Fenofibrate Trial Aims to Prevent Worsening of Diabetic Retinopathy
A randomized trial is evaluating fenofibrate's efficacy in preventing worsening of diabetic retinopathy over 6 years.
Asset / Drug
Drug and asset intelligence for Fenofibrate with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.